<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3"><gtr:id>F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3</gtr:id><gtr:name>Swiss Group for Cancer Clinical Research (SAKK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/666A7C6D-E59C-4C37-8997-490B93914C41"><gtr:id>666A7C6D-E59C-4C37-8997-490B93914C41</gtr:id><gtr:name>MRC Clinical Trials Unit</gtr:name><gtr:address><gtr:line1>Aviation House</gtr:line1><gtr:line2>125 Kingsway</gtr:line2><gtr:postCode>WC2B 6NH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82321AD2-CD2E-456C-9395-59CF155A3EC8"><gtr:id>82321AD2-CD2E-456C-9395-59CF155A3EC8</gtr:id><gtr:name>Sanofi</gtr:name><gtr:address><gtr:line1>174 avenue de France</gtr:line1><gtr:line4>Paris cedex 13</gtr:line4><gtr:postCode>75635</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C"><gtr:id>72F4A4EA-BEBF-47BB-AC75-CD8157D7B17C</gtr:id><gtr:name>Tata Memorial Hospital</gtr:name><gtr:address><gtr:line1>Cancer Research Centre</gtr:line1><gtr:line2>Dr. E Borges Road</gtr:line2><gtr:postCode>400 012</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9FE0E616-6A75-4DCC-BA07-3ADF018A9669"><gtr:id>9FE0E616-6A75-4DCC-BA07-3ADF018A9669</gtr:id><gtr:name>National Cancer Research Institute</gtr:name><gtr:address><gtr:line1>National Cancer Research Institute</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B589281B-BE51-4D64-96A8-B62BDE6E23AB"><gtr:id>B589281B-BE51-4D64-96A8-B62BDE6E23AB</gtr:id><gtr:name>Canadian Cancer Society Research Institute (CCSRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3"><gtr:id>F69DF9A0-A5B2-48F3-BA8F-2D42430D41F3</gtr:id><gtr:name>Swiss Group for Cancer Clinical Research (SAKK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/274F2FB0-27BB-4991-A894-796A2AE916E3"><gtr:id>274F2FB0-27BB-4991-A894-796A2AE916E3</gtr:id><gtr:name>The Christie NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Wilmslow Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M20 4BX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD698BE9-1ED7-42BF-AC5D-427A5CA5851D"><gtr:id>DD698BE9-1ED7-42BF-AC5D-427A5CA5851D</gtr:id><gtr:name>Bayer</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3591B22B-5D64-4E64-88AB-6FF834EBF6BF"><gtr:id>3591B22B-5D64-4E64-88AB-6FF834EBF6BF</gtr:id><gtr:firstName>Ruth</gtr:firstName><gtr:otherNames>Elizabeth</gtr:otherNames><gtr:surname>Langley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9"><gtr:id>A415FBFD-F657-4BE1-B8B7-33C8B25DA5E9</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Sydes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C13466CE-B313-46BD-98D4-E9AA5E40CBC2"><gtr:id>C13466CE-B313-46BD-98D4-E9AA5E40CBC2</gtr:id><gtr:firstName>Rhian</gtr:firstName><gtr:surname>Gabe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0C59F358-7424-439C-BECF-3CF953EA65F3"><gtr:id>0C59F358-7424-439C-BECF-3CF953EA65F3</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Kaplan</gtr:surname><gtr:orcidId>0000-0002-0189-8348</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122861330"><gtr:id>300CC796-59A4-412C-85C9-AA8774AE9814</gtr:id><gtr:title>Improving outcomes for men with prostate cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122861330</gtr:grantReference><gtr:abstractText>We seek to improve outcomes, reduce side-effects and reduce over-diagnosis and over-treatment in the most common male cancer: prostate cancer.|Prostate cancer is a big problem. It is increasingly common (30,000 new UK cases in 2005), particularly earlier stages of disease. We need to improve outcomes.|In recent years, we have shown that bisphosphonate drugs may make men with metastases live longer, that men live longer if given radiotherapy with hormone therapy (the mainstay of treatment for more advanced disease) and that, in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern radiotherapy equipment.|We have 3 studies open to recruitment and one to open. STAMPEDE, for men starting hormone therapy, uses new research methods to assess three quite different drugs (chemotherapy, bone-protecting drug, cox-2 inhibitor) alone or in pairs, each with standard hormone therapy. PATCH is looking at a different way of giving hormone therapy to reduce toxicity and improve outcomes. RADICALS studies when and how best to use radiotherapy and hormone therapy after surgery (radical prostatectomy) for prostate cancer, balancing cancer outcomes with potential unwanted effects. The new study uses magnetic resonance imaging to diagnose cancers that require treatment from those that do not.</gtr:abstractText><gtr:technicalSummary>We seek to improve outcomes, reduce side-effects and reduce over-diagnosis and over-treatment in the most common male cancer: prostate cancer.|Prostate cancer is a big problem. It is increasingly common (30,000 new UK cases in 2005), particularly with diagnosis of earlier stages of disease. Most men may develop prostate cancer if they live sufficiently long. The prognosis for men with clinically relevant, high-risk prostate cancer has not greatly improved for many years and requires studying. Many prostate tumours are slow growing and remain clinically unimportant. Men with early stage disease are likely to die with than of prostate cancer. Here, we must balance providing effective treatment with avoiding unwanted treatment side-effects. |Our programme aims to improve outcomes, especially survival, for men with prostate cancer using novel approaches or novel methods. We wish to reduce over-diagnosis of clinically irrelevant tumours and reduce over-treatment. We wish to design and implement methods for speeding up trials and prostate cancer is a good testing ground for this.|In recent years, we have shown that:|a first-generation bisphosphonate drug may make men with metastases live longer (PR05, ISRCTN38477744) but not men with earlier disease (PR04, ISRCTN61384873)|men live longer if given radiotherapy with hormone therapy, the mainstay of treatment for more advanced disease (PR07, NCIC PR.3, ISRCTN24991896)|in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern conformal radiotherapy methods (RT01, ISRCTN47772397). in men with less advanced disease, higher doses of radiotherapy can give better prostate cancer outcomes without increasing unwanted effects when using modern conformal radiotherapy methods (RT01, ISRCTN47772397).|We have 3 studies open to recruitment and one to open. STAMPEDE (MRC PR08, ISRCTN78818544) is a flagship trial for men starting long-term hormone therapy. It uses new multi-arm multi-stage (MAMS) methods to supplement standard hormone therapy with 5 combinations of 3 drugs: doctaxel (a taxane chemotherapy), zoledronic acid (a potent, third-generation bisphosphonate) and celecoxib (a selective cox-2 inhibitor). More than 1500 patients from the UK and Switzerland have already joined this 6-arm trial.|PATCH (PR09, ISRCTN70406718) looks at whether oestrogen-based therapy can be administered more safely using patches rather than tablets; this method bypasses the liver pathways and cardiovascular problems should be reduced and efficacy improved. This is a novel idea. PATCH reached its target of 250 patients and will continue further.|RADICALS (PR10, NCIC PR-13, ISRCTN40814031) assesses two important questions for men who have chosen radical prostatectomy for localised prostate cancer: (i) the use and timing of post-operative radiotherapy, balancing potential efficacy and potential over-treatment; and (ii) the use of hormone therapy with any post-operative radiotherapy. RADICALS will recruit around 4,000 men from the UK, Canada, Denmark and beyond.|The new study evaluates multi-functional MRI in the diagnosis and characterisation of prostate cancer with a view to reducing over-diagnosis of clinically irrelevant tumours and over-treatment.</gtr:technicalSummary><gtr:fund><gtr:end>2013-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>4034322</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>NCIC PR.3 / MRC PR07 trial (NCT00002633)</gtr:description><gtr:id>B6B60A63-3BC7-49CD-9E9C-BE8A89E04009</gtr:id><gtr:impact>Clinical trial successfully recruited. Intermediate results released by IDMC and presented as abstracts at ASCO, ASTRO and NCRI conferences in 2010. Paper published in 2011: 22056152. Final results pending publication.
Results show how hundreds of life years have been saved by sites acting on these findings.</gtr:impact><gtr:outcomeId>FAB402A9B6C-2</gtr:outcomeId><gtr:partnerContribution>Design, central coordination and analysis of trial

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial. 

Long-term results will be published in a high-impact oncology journal late in 2014 (provisional acceptance). A companion quality of life paper has been submitted to the same journal. A paper on the impact of the findings has been submitted in Oct-2014</gtr:partnerContribution><gtr:piContribution>Revision of design; coordination of UK elements of trial; scientific input and interpretation.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>C451156E-8F21-4A92-A4EC-910E156045FD</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-2</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Cancer Society Research Institute (CCSRI)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>NCIC PR.3 / MRC PR07 trial (NCT00002633)</gtr:description><gtr:id>3B4BCD26-A8CB-497D-9918-1CA2F03D3F98</gtr:id><gtr:impact>Clinical trial successfully recruited. Intermediate results released by IDMC and presented as abstracts at ASCO, ASTRO and NCRI conferences in 2010. Paper published in 2011: 22056152. Final results pending publication.
Results show how hundreds of life years have been saved by sites acting on these findings.</gtr:impact><gtr:outcomeId>FAB402A9B6C-1</gtr:outcomeId><gtr:partnerContribution>Design, central coordination and analysis of trial

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial. 

Long-term results will be published in a high-impact oncology journal late in 2014 (provisional acceptance). A companion quality of life paper has been submitted to the same journal. A paper on the impact of the findings has been submitted in Oct-2014</gtr:partnerContribution><gtr:piContribution>Revision of design; coordination of UK elements of trial; scientific input and interpretation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>A594078A-2C1D-41F1-A3BE-5C646521FA17</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-7</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Janssen-Cilag</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>56AAE783-4B23-4071-B1FE-C8B4FDDDD3F6</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-8</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>PATCH (MRC PR09) trial (NCT00303784)</gtr:description><gtr:id>676FC82E-5E5F-42EA-AFAD-2557789C946A</gtr:id><gtr:impact>This is a multidisciplinary clinical trial (oncology, urology, pathology, statistics, operations). Recruitment to the trial is ongoing and so the principal outcomes have not yet been realised. Outputs to date include publication of a systematic review, as well as some early data from the trial (PMIDs: 18422771, 18268497), and presentation of the results of the first stage of the study at a number of national and international conferences in 2011.</gtr:impact><gtr:outcomeId>C7216957D2B-1</gtr:outcomeId><gtr:partnerContribution>The trial is supported by the National Cancer Research Institute Prostate Clinical Studies Group. It is a collaboration with the National Cancer Research Network (NCRN, a component of NIHR and funded by the English Dept of Health) and corresponding networks in the other UK nations, and specifically includes all the staff at each of the clinical sites that are participating in the trial. Each site identifies patients potentially suitable for the trial, obtains informed consent, treats and follows up patients within the trial, and provides data through completion and return of case report forms. The NCRN provides infrastructure funding for clinical trials. Imperial College is the sponsor of the trial and Cancer Research UK provide funding for the trial.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>0667A312-C955-4603-844E-4FB4E104A0A3</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-3</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>PR04 and PR05 trials (ISRCTN61384873, ISRCTN38477744)</gtr:description><gtr:id>25DBD5F4-B50D-44E7-A854-76AC1327362C</gtr:id><gtr:impact>Published results of led to the development of the STAMPEDE trial (NCT00268476) 19674936 12953084 17505072 

Long-term results have been published in 2009. No further follow-up will happen at trial sites</gtr:impact><gtr:outcomeId>897002149E5-1</gtr:outcomeId><gtr:partnerContribution>Roche: Free drug and distribution, plus an educational grant

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation of PR04 and PR05 trials</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>F3E7FAEB-985D-4AE0-93BB-5CEA09F6056D</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-5</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>2DCDA290-1466-463B-A375-6CA99AF50D80</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-3</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>NCIC PR.3 / MRC PR07 trial (NCT00002633)</gtr:description><gtr:id>7333BA92-5D21-43D8-BE3B-4D71F51C28E7</gtr:id><gtr:impact>Clinical trial successfully recruited. Intermediate results released by IDMC and presented as abstracts at ASCO, ASTRO and NCRI conferences in 2010. Paper published in 2011: 22056152. Final results pending publication.
Results show how hundreds of life years have been saved by sites acting on these findings.</gtr:impact><gtr:outcomeId>FAB402A9B6C-3</gtr:outcomeId><gtr:partnerContribution>Design, central coordination and analysis of trial

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial. 

Long-term results will be published in a high-impact oncology journal late in 2014 (provisional acceptance). A companion quality of life paper has been submitted to the same journal. A paper on the impact of the findings has been submitted in Oct-2014</gtr:partnerContribution><gtr:piContribution>Revision of design; coordination of UK elements of trial; scientific input and interpretation.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>54F7DF81-D91E-4CDE-9392-36605D6C5E61</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-6</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PROMIS (MRC PR11) study</gtr:description><gtr:id>9BECA0A2-8B32-4D81-BA38-AD0060BA6BE1</gtr:id><gtr:impact>Study now in pilot phase and an additional 5 sites are opening. Central review of pathology and imaging will be done at UCL, and all data collated and analysed by MRC CTU.</gtr:impact><gtr:outcomeId>KPiC2VR9vQb-4</gtr:outcomeId><gtr:partnerContribution>PROMIS is run in collaboration with the NCRI prostate cancer CSG which encourages national participation in the trialThis trial is a collaboration with the NCRN which provides infrastructure support for conducting studies in sites across the UKThe MRC CTU and UCL jointly developed and designed PROMIS. The NIHR grant of &amp;pound;2,340,212&amp;nbsp;is split between UCL who are study sponsors and the MRC CTU who have delegated authority to coordinate and analyse the study. UCL will also be one of the main centres recruiting patients. Participating sites are responsible for identification, consent and registering of PROMIS patients, administration of protocol procedures, management and follow up of patients and provision of patient study data through completion of MRC CTU designed case report forms.ICR has received funding from the Prostate Cancer Charity for the collection, storage and analsysis of samples provided by consenting patients in the PROMIS study. MRC CTU, UCL and ICR will be collaborating to facilitate translational research arising from PROMIS, especially in relation to biomarkers.</gtr:partnerContribution><gtr:piContribution>Scientific design, coordination, analysis and interpretation of PROMIS trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bayer</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bayer HealthCare</gtr:department><gtr:description>Add-Aspirin trial - Bayer Pharmaceuticals PLC</gtr:description><gtr:id>704A55AE-2599-4A18-A999-BB4895EFD214</gtr:id><gtr:impact>Contract signed, no output to date. The trial is currently in set-up.</gtr:impact><gtr:outcomeId>5459faf5da2257.86001473-1</gtr:outcomeId><gtr:partnerContribution>Bayer Pharmaceuticals are supplying the Add-Aspirin trial medication (100mg aspirin tablets, 300mg aspirin tablets and matched placebos) free of charge.</gtr:partnerContribution><gtr:piContribution>We approached Bayer to supply the drugs for the Add-Aspirin trial.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PROMIS (MRC PR11) study</gtr:description><gtr:id>2E518D68-D757-4203-B064-5735C3448474</gtr:id><gtr:impact>Study now in pilot phase and an additional 5 sites are opening. Central review of pathology and imaging will be done at UCL, and all data collated and analysed by MRC CTU.</gtr:impact><gtr:outcomeId>KPiC2VR9vQb-3</gtr:outcomeId><gtr:partnerContribution>PROMIS is run in collaboration with the NCRI prostate cancer CSG which encourages national participation in the trialThis trial is a collaboration with the NCRN which provides infrastructure support for conducting studies in sites across the UKThe MRC CTU and UCL jointly developed and designed PROMIS. The NIHR grant of &amp;pound;2,340,212&amp;nbsp;is split between UCL who are study sponsors and the MRC CTU who have delegated authority to coordinate and analyse the study. UCL will also be one of the main centres recruiting patients. Participating sites are responsible for identification, consent and registering of PROMIS patients, administration of protocol procedures, management and follow up of patients and provision of patient study data through completion of MRC CTU designed case report forms.ICR has received funding from the Prostate Cancer Charity for the collection, storage and analsysis of samples provided by consenting patients in the PROMIS study. MRC CTU, UCL and ICR will be collaborating to facilitate translational research arising from PROMIS, especially in relation to biomarkers.</gtr:partnerContribution><gtr:piContribution>Scientific design, coordination, analysis and interpretation of PROMIS trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astellas Pharma</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>7D52C771-2ACA-48BC-86ED-10231CBC1128</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-9</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>PR04 and PR05 trials (ISRCTN61384873, ISRCTN38477744)</gtr:description><gtr:id>C659E001-5CA7-4E19-97B1-26418EC9685D</gtr:id><gtr:impact>Published results of led to the development of the STAMPEDE trial (NCT00268476) 19674936 12953084 17505072 

Long-term results have been published in 2009. No further follow-up will happen at trial sites</gtr:impact><gtr:outcomeId>897002149E5-2</gtr:outcomeId><gtr:partnerContribution>Roche: Free drug and distribution, plus an educational grant

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation of PR04 and PR05 trials</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanofi</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Aventis</gtr:department><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>6E01DC04-9F4D-4F58-8DAC-C02D090BD26F</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-1</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>RT01 trial and RAPPER (NCT19836155)</gtr:description><gtr:id>70CAF32D-2A71-487A-9DB1-0F3BAAC57A2B</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, physics, radiography, statistics, operations. Various publications: 15297138, 15622611, 16828908, 16949694, 17155990, 17391791, 17482880, 18343725, 18565744, 19540054, 19826203, 19836155, 20092961, 20096945, 21470834, 24974847, 24785509.</gtr:impact><gtr:outcomeId>B3CD32461E5-3</gtr:outcomeId><gtr:partnerContribution>Design and development of physics-based substudies using data from RT01
Design and running of RAPPER study to which many RT01 patients have contributed blood samples and RT01 trial toxicity data are provided

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination, analysis and scientific interpretation of RT01 trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>313AECD0-4CB8-4DD7-9E27-E03AE4DA2AC5</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-4</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>PATCH (MRC PR09) trial (NCT00303784)</gtr:description><gtr:id>35F9212E-774F-4E4F-86A4-B4DC45AF99F7</gtr:id><gtr:impact>This is a multidisciplinary clinical trial (oncology, urology, pathology, statistics, operations). Recruitment to the trial is ongoing and so the principal outcomes have not yet been realised. Outputs to date include publication of a systematic review, as well as some early data from the trial (PMIDs: 18422771, 18268497), and presentation of the results of the first stage of the study at a number of national and international conferences in 2011.</gtr:impact><gtr:outcomeId>C7216957D2B-3</gtr:outcomeId><gtr:partnerContribution>The trial is supported by the National Cancer Research Institute Prostate Clinical Studies Group. It is a collaboration with the National Cancer Research Network (NCRN, a component of NIHR and funded by the English Dept of Health) and corresponding networks in the other UK nations, and specifically includes all the staff at each of the clinical sites that are participating in the trial. Each site identifies patients potentially suitable for the trial, obtains informed consent, treats and follows up patients within the trial, and provides data through completion and return of case report forms. The NCRN provides infrastructure funding for clinical trials. Imperial College is the sponsor of the trial and Cancer Research UK provide funding for the trial.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PATCH (MRC PR09) trial (NCT00303784)</gtr:description><gtr:id>1A613B40-41C0-4068-9F23-7485007204CC</gtr:id><gtr:impact>This is a multidisciplinary clinical trial (oncology, urology, pathology, statistics, operations). Recruitment to the trial is ongoing and so the principal outcomes have not yet been realised. Outputs to date include publication of a systematic review, as well as some early data from the trial (PMIDs: 18422771, 18268497), and presentation of the results of the first stage of the study at a number of national and international conferences in 2011.</gtr:impact><gtr:outcomeId>C7216957D2B-2</gtr:outcomeId><gtr:partnerContribution>The trial is supported by the National Cancer Research Institute Prostate Clinical Studies Group. It is a collaboration with the National Cancer Research Network (NCRN, a component of NIHR and funded by the English Dept of Health) and corresponding networks in the other UK nations, and specifically includes all the staff at each of the clinical sites that are participating in the trial. Each site identifies patients potentially suitable for the trial, obtains informed consent, treats and follows up patients within the trial, and provides data through completion and return of case report forms. The NCRN provides infrastructure funding for clinical trials. Imperial College is the sponsor of the trial and Cancer Research UK provide funding for the trial.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RT01 trial and RAPPER (NCT19836155)</gtr:description><gtr:id>93415B45-3133-4AD9-AA6F-F830CFF4C9D6</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, physics, radiography, statistics, operations. Various publications: 15297138, 15622611, 16828908, 16949694, 17155990, 17391791, 17482880, 18343725, 18565744, 19540054, 19826203, 19836155, 20092961, 20096945, 21470834, 24974847, 24785509.</gtr:impact><gtr:outcomeId>B3CD32461E5-1</gtr:outcomeId><gtr:partnerContribution>Design and development of physics-based substudies using data from RT01
Design and running of RAPPER study to which many RT01 patients have contributed blood samples and RT01 trial toxicity data are provided

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination, analysis and scientific interpretation of RT01 trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Add-Aspirin Trial</gtr:description><gtr:id>D0DA85C7-7A5E-4A4B-B270-5C6ACF1F8CD3</gtr:id><gtr:impact>trial in setup phase</gtr:impact><gtr:outcomeId>W6ggX9gRfo2-1</gtr:outcomeId><gtr:partnerContribution>funding from CRUK for Add-Aspirin Trial</gtr:partnerContribution><gtr:piContribution>application for Add-Aspirin trial funding</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Cancer Research Network (NCRN)</gtr:department><gtr:description>PROMIS (MRC PR11) study</gtr:description><gtr:id>EF22290F-F92C-4719-99D7-30DCE409ADC1</gtr:id><gtr:impact>Study now in pilot phase and an additional 5 sites are opening. Central review of pathology and imaging will be done at UCL, and all data collated and analysed by MRC CTU.</gtr:impact><gtr:outcomeId>KPiC2VR9vQb-2</gtr:outcomeId><gtr:partnerContribution>PROMIS is run in collaboration with the NCRI prostate cancer CSG which encourages national participation in the trialThis trial is a collaboration with the NCRN which provides infrastructure support for conducting studies in sites across the UKThe MRC CTU and UCL jointly developed and designed PROMIS. The NIHR grant of &amp;pound;2,340,212&amp;nbsp;is split between UCL who are study sponsors and the MRC CTU who have delegated authority to coordinate and analyse the study. UCL will also be one of the main centres recruiting patients. Participating sites are responsible for identification, consent and registering of PROMIS patients, administration of protocol procedures, management and follow up of patients and provision of patient study data through completion of MRC CTU designed case report forms.ICR has received funding from the Prostate Cancer Charity for the collection, storage and analsysis of samples provided by consenting patients in the PROMIS study. MRC CTU, UCL and ICR will be collaborating to facilitate translational research arising from PROMIS, especially in relation to biomarkers.</gtr:partnerContribution><gtr:piContribution>Scientific design, coordination, analysis and interpretation of PROMIS trials</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Group for Cancer Clinical Research (SAKK)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>FD3EB002-1DC7-45BB-8FF5-E0A494F4D0C0</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-4</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PROMIS (MRC PR11) study</gtr:description><gtr:id>8B4FB125-B357-4BB7-8461-91557F54DCD8</gtr:id><gtr:impact>Study now in pilot phase and an additional 5 sites are opening. Central review of pathology and imaging will be done at UCL, and all data collated and analysed by MRC CTU.</gtr:impact><gtr:outcomeId>KPiC2VR9vQb-1</gtr:outcomeId><gtr:partnerContribution>PROMIS is run in collaboration with the NCRI prostate cancer CSG which encourages national participation in the trialThis trial is a collaboration with the NCRN which provides infrastructure support for conducting studies in sites across the UKThe MRC CTU and UCL jointly developed and designed PROMIS. The NIHR grant of &amp;pound;2,340,212&amp;nbsp;is split between UCL who are study sponsors and the MRC CTU who have delegated authority to coordinate and analyse the study. UCL will also be one of the main centres recruiting patients. Participating sites are responsible for identification, consent and registering of PROMIS patients, administration of protocol procedures, management and follow up of patients and provision of patient study data through completion of MRC CTU designed case report forms.ICR has received funding from the Prostate Cancer Charity for the collection, storage and analsysis of samples provided by consenting patients in the PROMIS study. MRC CTU, UCL and ICR will be collaborating to facilitate translational research arising from PROMIS, especially in relation to biomarkers.</gtr:partnerContribution><gtr:piContribution>Scientific design, coordination, analysis and interpretation of PROMIS trials</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Tata Memorial Hospital</gtr:collaboratingOrganisation><gtr:country>India, Republic of</gtr:country><gtr:description>Add-Aspirin - Tata Memorial Hospital</gtr:description><gtr:id>465CF16A-5BB5-456E-A006-17A3F567BB9D</gtr:id><gtr:impact>In terms of the Add-Aspirin trial, the collaboration will speed up delivery of the research and enable demonstration of the health intervention in a range of settings, increasing the potential global impact of the results. Additionally, the work is facilitating development of a cancer research network in India and will pave the way for future collaborative projects.</gtr:impact><gtr:outcomeId>5459f8d38b2a80.40216637-1</gtr:outcomeId><gtr:partnerContribution>Management and oversight of the Add-Aspirin trial in India.</gtr:partnerContribution><gtr:piContribution>Leading the Add-Aspirin trial; management of the trial in the UK; oversight and mentoring of the research group at the Tata Memorial Hospital who will manage Indian participation in the trial.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>PATCH (MRC PR09) trial (NCT00303784)</gtr:description><gtr:id>8D7B675D-2871-4212-AF62-5CBB80FC8D87</gtr:id><gtr:impact>This is a multidisciplinary clinical trial (oncology, urology, pathology, statistics, operations). Recruitment to the trial is ongoing and so the principal outcomes have not yet been realised. Outputs to date include publication of a systematic review, as well as some early data from the trial (PMIDs: 18422771, 18268497), and presentation of the results of the first stage of the study at a number of national and international conferences in 2011.</gtr:impact><gtr:outcomeId>C7216957D2B-4</gtr:outcomeId><gtr:partnerContribution>The trial is supported by the National Cancer Research Institute Prostate Clinical Studies Group. It is a collaboration with the National Cancer Research Network (NCRN, a component of NIHR and funded by the English Dept of Health) and corresponding networks in the other UK nations, and specifically includes all the staff at each of the clinical sites that are participating in the trial. Each site identifies patients potentially suitable for the trial, obtains informed consent, treats and follows up patients within the trial, and provides data through completion and return of case report forms. The NCRN provides infrastructure funding for clinical trials. Imperial College is the sponsor of the trial and Cancer Research UK provide funding for the trial.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination, analysis and interpretation</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Christie NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RT01 trial and RAPPER (NCT19836155)</gtr:description><gtr:id>53AFA36A-E036-4B2D-8AE5-BA3B205C5700</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, physics, radiography, statistics, operations. Various publications: 15297138, 15622611, 16828908, 16949694, 17155990, 17391791, 17482880, 18343725, 18565744, 19540054, 19826203, 19836155, 20092961, 20096945, 21470834, 24974847, 24785509.</gtr:impact><gtr:outcomeId>B3CD32461E5-2</gtr:outcomeId><gtr:partnerContribution>Design and development of physics-based substudies using data from RT01
Design and running of RAPPER study to which many RT01 patients have contributed blood samples and RT01 trial toxicity data are provided

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination, analysis and scientific interpretation of RT01 trial</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Research Institute (NCRI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>NCRI Prostate Cancer CSG</gtr:department><gtr:description>RT01 trial and RAPPER (NCT19836155)</gtr:description><gtr:id>38A3EAF0-D767-41EA-8184-FCFD29B199CE</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, physics, radiography, statistics, operations. Various publications: 15297138, 15622611, 16828908, 16949694, 17155990, 17391791, 17482880, 18343725, 18565744, 19540054, 19826203, 19836155, 20092961, 20096945, 21470834, 24974847, 24785509.</gtr:impact><gtr:outcomeId>B3CD32461E5-4</gtr:outcomeId><gtr:partnerContribution>Design and development of physics-based substudies using data from RT01
Design and running of RAPPER study to which many RT01 patients have contributed blood samples and RT01 trial toxicity data are provided

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination, analysis and scientific interpretation of RT01 trial</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>STAMPEDE (MRC PR08) trial (NCT00268476)</gtr:description><gtr:id>9F7B5ADA-26CE-4138-80EC-9CA8E15EB6B9</gtr:id><gtr:impact>Clinical trial. 
Multi-disciplinary: oncology, urology, statistics, operations. Results awaited; accrual ongoing. 
Outputs relate to promoting methodology: all listed above. PubMed ID 19519885. PubMed ID 18990168. PubMed ID 18760574. 
Efforts to collaborate with a Japanese research group were unsuccessful (PubMed ID 21615523), as were efforts to engage other European organisation
Recent editorial: 24985962
 
Recruitment was stopped early to two research arms following a pre-planned interim analysis. Publications are in development. Research was activated to a new research comparison in Nov-2011; and a further new research comparison will be activated in Jan-2013.</gtr:impact><gtr:outcomeId>A50A89713D7-2</gtr:outcomeId><gtr:partnerContribution>Pfizer: Free drug (celecoxib) and some money for distribution through Bilcare, plus educational grant.

Sanofi-Aventis: Discounted drug (docetaxel) for UK. Free drug for Switzerland and some money for distribution through Bilcare, plus educational grant.

Novartis: Free drug (zoledronic acid) distributed directly, plus educational grant.

Janssen: Free drug (abiraterone) and full distribution costs through B&amp;amp;C, plus educational grant.

Astellas (from Jul-2014): Free drug (enzalutamide) and full distribution costs through Bilcare, plus educational grant

SAKK: Data management and coordination in Switzerland

NCRI/NCRN: This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. STAMPEDE is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial.

Sites: Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.</gtr:partnerContribution><gtr:piContribution>Scientific design, central coordination and analysis of the STAMPEDE trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Canadian Cancer Society Research Institute (CCSRI)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>RADICALS (MRC PR10) trial (NCT00541047)</gtr:description><gtr:id>77CF8BD8-4FE0-41A9-848E-136EBC616910</gtr:id><gtr:impact>Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC).</gtr:impact><gtr:outcomeId>9C39D20CA4A-1</gtr:outcomeId><gtr:partnerContribution>Coordination of RADICALS trial in Canada

This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial</gtr:partnerContribution><gtr:piContribution>Design, central coordination and analysis of the RADICALS trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Results of MRC RT01 trial (participants)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7CFAF4AD-ED59-45AA-97FB-1A5A3227FBFD</gtr:id><gtr:impact>Results of the MRC RT01 trial were provided to doctors to pass on to patients and families

No direct feedback</gtr:impact><gtr:outcomeId>634AA26F022</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical trials in prostate cancer - Basingstoke patient support group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3F1639A4-9BDD-44C5-8A92-698416B34F03</gtr:id><gtr:impact>50 patients attended a talk on clinical trials, primarily prostate cancer. There was much interaction and many questions.

Led to talks in Manchester and Norwich</gtr:impact><gtr:outcomeId>TfnkFQ525mT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate Cancer Support Federation newsletter (PATCH trial)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5D18A14E-223F-4DD7-BA73-8D4CC538BFF2</gtr:id><gtr:impact>The Prostate Cancer Support Federation (PCSF) is an organisation of UK patient-led prostate cancer support groups. An article on the PATCH trial was published in the PCSF newsletter with the aim of raising awareness of the trial, the aim of the research, and the results it has produced so far, amongst prostate cancer patients.

This, and other similar activities, have established good links with the PCSF, providing a route for future engagement with the prostate cancer patient community about CTU research.</gtr:impact><gtr:outcomeId>CxHjD2vcZxc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Application of MAMS trials into practice: the STAMPEDE experience (extended issues)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86BA45C8-1AE6-496E-AD9B-88D6C928E402</gtr:id><gtr:impact>Presentations to other researchers who could use these methods at (1) MRC Methodology Hubs meeting, (2) Workshop on time-to-event data, (3) 1st UK Clinical Trials Methodology Conference
See another row that gives more details information.

Number of people contacting MRC CTU to ask about multi-arm multi-stage trials has increased</gtr:impact><gtr:outcomeId>Mf6s8EWB8sq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical trials in prostate cancer - Norwich patient support group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>24E1AB22-4BBB-43D4-8AD7-DF6FD8E9F6F0</gtr:id><gtr:impact>50 patients attended a talk on clinical trials, primarily prostate cancer. There was much interaction and many questions

Increased awareness of research</gtr:impact><gtr:outcomeId>oMqCSkeyC8M</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PATCH poster presentations at ASCO 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CBA7FD6D-B444-417C-8A49-A6BFBCB637A8</gtr:id><gtr:impact>PATCH had the following poster presentations at ASCO May 2014 (Chicago, US):
- Bone density in men receiving androgen deprivation therapy for prostate cancer, a randomised comparison between transdermal estrogen and luteinising hormone-releasing hormone agonists 
- PATCH (Prostate Adenocarcinoma: TransCutaneous Hormones, PR09): A randomised controlled trial of transdermal estrogen patches versus luteinising hormone releasing hormone agonists in locally advanced and metastatic prostate cancer

The poster presentations led to several new sites expressing interests in joining the study.</gtr:impact><gtr:outcomeId>54578365cc8373.61804584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://meetinglibrary.asco.org/content/131497-144</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Impact of radiotherapy on node-positive prostate cancer: data from the control arm of STAMPEDE</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDD61239-FFCB-4E7B-B582-893B003F5319</gtr:id><gtr:impact>More than 1000 relevant people viewed the presentations. Discussions were stimulated. A paper is in development.

None yet (Nov-2014)</gtr:impact><gtr:outcomeId>5458ee07e45a61.74755739</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://annonc.oxfordjournals.org/content/25/suppl_4/iv255.2.abstract</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Update on clinical trials in prostate cancer to charities</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F67537EE-8777-400A-98D6-057137858009</gtr:id><gtr:impact>Representatives from 4 major charities attended to hear results from PR07 and RT01 and to be updated on ongoing research at MRC CTU.
Organised by Annabelle South and Matt Sydes.

Agreed to similar updates in the future.</gtr:impact><gtr:outcomeId>JD3FUdRKBvC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Results of MRC PR04/5 trials</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6956BEA7-00BE-49E9-AC6D-75B03C53C941</gtr:id><gtr:impact>The results of the MRC PR04 and PR05 trials were summarised and provided to doctors to give to their patients or families. Printed in 2007; updated in 2009

No direct feedback</gtr:impact><gtr:outcomeId>5721A521B78</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Importance of clinical trials - Prostate Cancer Charity annual conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F9EE926-6638-4FCB-9B4B-C64201559915</gtr:id><gtr:impact>Presentation on clinical trials to around 400 men with prostate cancer and their families

Generally well received</gtr:impact><gtr:outcomeId>WuCXYtgtB4z</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PATCH presentation at STAMPEDE Investigators Meeting 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>ADFC4EF1-5F69-4212-B247-F4C36FBB80E6</gtr:id><gtr:impact>A presentation of the PATCH trial highlighting the phase III extension and promoting recruitment was given at a number of regional meetings for the STAMPEDE trial investigators.

There were interests from new sites to join the study.</gtr:impact><gtr:outcomeId>545786dcb47747.29984108</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Application of MAMS trials into practice: the STAMPEDE experience (ongoing)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D97D8FDB-3702-4576-9619-C16FC35F5F79</gtr:id><gtr:impact>There have been multiple presentations on STAMPEDE and the implementation of the MAMS design. For example, below are 36 completed or planned presentations by Trial Statistician, Matt Sydes. There are have been multiple other presentations, notably by Chief Investigator, Nick James, and CTU Director, Max Parmar.

 Date Presentation Format Meeting &amp;amp; Venue
========================================================================================
Jan2006 MAMS trials Invited External SPCG annual meeting Stockholm, Swe
Sep2006 STAMPEDE design Invited External Colin Blakemore visit MRC CTU
Apr2007 STAMPEDE design Invited External STAMPEDE launch meeting London
Oct2007 MAMS &amp;amp; STAMPEDE Invited Internal Senior staff awayday RSS
Feb2008 MAMS &amp;amp; STAMPEDE Invited Internal Prostate group meeting MRC CTU
Nov2008 STAMPEDE design Invited External Stephen Holgate visit MRC CTU
Feb2009 MAMS trials and STAMPEDE Invited External Futility &amp;amp; lack-of-benefit MRC CTU
Jul2009 STAMPEDE Invited Internal Background to STAMPEDE design MRC CTU
Jul2009 STAMPEDE design Invited External STAMPEDE joint TSC &amp;amp; IDMC meetin London
Oct2009 Implementation of MAMS trials Invited External GSK annual global stats conferen London
Feb2010 Implementation of MAMS trials Invited External GSK UK meeting London
Mar2010 Design of MAMS trials Invited External EURAMOS Strategy Group meeting: London
May2010 Design of MAMS trials Invited External Paed Onc Stats Birmingham
Jun2010 Design of MAMS trials Invited External Seminar at Institut Gustav Rouss Paris, FR
Oct2010 STAMPEDE design Invited External STAMPEDE planning with Janssen Milan, It
Oct2010 STAMPEDE and abiraterone Invited External STAMPEDE planning with Janssen Milan, It
Jan2011 Practical Implementation of MAMS trials Invited External MRC Methods Hub Annual Meeting Birmingham
Feb2011 Statistical Implementation of MAMS trials Invited External London Hub Workship London
Jun2011 MAMS trials Invited External 6th Accredited CTUs meeting London
Oct2011 Practical Implementation of MAMS trials Submitted External Methodology Conference Bristol
Jun2011 STAMPEDE: adding abiraterone Invited External STAMPEDE planning with Janssen MRC CTU
Oct2011 MAMS trials Invited Internal Sir John Chisholm visit to CTU London
Jul2012 Practical Implementation of MAMS trials Submitted External Adaptive Trials and Multiple Com Heidelberg, Ger
Jul2012 Changes to STAMPEDE Invited Internal Cancer and Non-Infectious Diseas MRC CTU
Oct2012 MAMS trials and rare diseases Invited External RSS Medical Section RSS, London
Nov2012 Practical Implementation of MAMS trials Invited External MAMS trials workshop MRC CTU
Jan2013 MAMS trials Invited External LSHTM/CTU workshop MRC CTU
Feb2013 Plans for new arm in STAMPEDE Invited Internal Cancer and Non-Infectious Diseas MRC CTU
Mar2013 MAMS trial strategy Invited External PSP workshop London
Sep2013 MAMS trials and rare diseases Invited External IRCI workshop on trial methods f Amsterdam, NL
Nov2013 Multi-arm trials Submitted External 2nd Clinical Trials Methodology Edinburgh
Feb2014 MAMS trials Invited External Royal Free Hospital statistical London
May2014 Multi-arm trials Submitted External Society for Clinical Trials (SCT Philadelphia, PA
Oct2014 MAMS trials Invited External HTMR Network PhD meeting London
Oct2014 MAMS trials Invited External Surgical meeting Birmingham
Sep2015 MAMS trials and rare cancers Invited External ECCO 2015 Vienna


Increasing awareness of the multi-arm multi-stage design for randomised controlled trials and its implementability.</gtr:impact><gtr:outcomeId>XY8qwg1mn1W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient engagement workshop - centenary celebrations</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A625ECF7-8407-4242-AC90-2341320D511C</gtr:id><gtr:impact>Discussed research. MSy involved in discussions re STAMPEDE and RADICALS.

Uncertain</gtr:impact><gtr:outcomeId>o5PYwoMdb2Z</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Results of MRC PR07 trial (participants)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>424B7FAF-D30B-4B0A-913A-17C74876B517</gtr:id><gtr:impact>Results summaries developed with consumers and sent to participating sites for dissemination directly to participants and relevant family members

None</gtr:impact><gtr:outcomeId>HikRrV1YEXa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical trials statistics for CancerHelp</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8AA3B28C-691C-4588-83BB-E29F2294C55A</gtr:id><gtr:impact>Attend by CRUK's CancerHelp nurses and managers. Given by Matt Sydes.

Lots of comments, questions and useful discussion</gtr:impact><gtr:outcomeId>oYhDfWssuk1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Add-Aspirin trial launch meeting at NCRI conference Liverpool 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>26D97812-19B9-46DE-A532-833D632F40D0</gtr:id><gtr:impact>Add-Aspirin trial launch meeting- Trial promotion and training for research nurses and doctors hoping to participate in the trial at their site.

Increased requests for further information from sites interested in participating in the trial.</gtr:impact><gtr:outcomeId>545a094ba7c251.42319641</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prostate cancer research at MRC CTU - Meeting with charity/patient group representatives</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E962B2EE-34DD-4A63-AA2F-46C0A3B044D0</gtr:id><gtr:impact>Representatives from prostate cancer charities and patient advocacy groups attended a meeting at the MRC Clinical Trials Unit to learn more about the ongoing and planned prostate cancer research at the unit, and to discuss future research priorities and collaborative activities between the CTU and the charities/patient groups.

Future collaborative engagement activities are being discussed.</gtr:impact><gtr:outcomeId>myXfkgT2E2m</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinical trials in prostate cancer - Manchester patient support group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7C1CE6E9-5383-4E76-AC10-4B7292FBB62F</gtr:id><gtr:impact>80 patients attended a talk on clinical trials, primarily prostate cancer. There was much interaction and many questions

None</gtr:impact><gtr:outcomeId>YT6H93BWxjy</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Results of MRC PR07 trial (media)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D855CFE0-5EA0-4039-BD2D-3A1DD199C22E</gtr:id><gtr:impact>Press release for PR07 results in Nov-2011. Led to some printed press coverage, at least one radio interview (Matt Sydes) and many on-line news article, plus one podcast interview.

Canadian collaborators independently put out press release and received more coverage including TV</gtr:impact><gtr:outcomeId>ncDJHkB1BCc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Results of MRC PR07 trial (policy)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>58242DB9-F9AD-48C0-8BEF-B7BFC4EB26F6</gtr:id><gtr:impact>New Policy and Research Impact Coordinator led development of Policy Brief aim at health professionals and policymakers

Results taken into updated NICE guidelines in the UK</gtr:impact><gtr:outcomeId>MsKnKjzhXPB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEMNet: Pimlico Academy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>185E6B7E-81D2-4F89-96FE-FB68AEC4F96E</gtr:id><gtr:impact>Talk about the importance of clinical trials to about 30 GSCE and A-level biology students at Pimlico Academy. Organised through STEMNet

Not known</gtr:impact><gtr:outcomeId>DwFGsmrwSjt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>139410</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Translational Research Committee (TRICC), STAMPEDE Bone Mineral Density Substudy</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>A84B56A5-8CA0-43A4-8246-5342459B22E7</gtr:id><gtr:outcomeId>D14791595210</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>898898</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK/CTAAC - STAMPEDE development and extension</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>CRUK/06/019 (additional)</gtr:fundingRef><gtr:id>AA5CE923-F5D4-4FBC-B5D1-76315496FDEC</gtr:id><gtr:outcomeId>G3mD5uouC3D</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prostate Cancer Charity -- RT01/PR07/The Prostate Cancer Charity, UK (via Institute of Cancer Research)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>BEA229CB-DF71-4FF4-959B-79AF5935D18E</gtr:id><gtr:outcomeId>sKxb9okBks90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Advisory and Awards Committee (CTAAC) -- STAMPEDE</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>CRUK/06/019 [A3804]</gtr:fundingRef><gtr:id>E80B6FA8-6117-4E6B-A0C4-050CA27D2E5B</gtr:id><gtr:outcomeId>8095300D2FC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>718007</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>Health Technology Assessment -- PROMIS/Health Technology Assessment</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>D77596A2-477F-46D8-B249-F9CD78CD6465</gtr:id><gtr:outcomeId>LYShYtm9n4Y0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1850000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Investigator initiated study (Janssen) -- STAMPEDE</gtr:description><gtr:end>2021-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>8F36CE0D-0999-4B9F-B7E0-FCE4BD924626</gtr:id><gtr:outcomeId>HhfLHyrYiMP0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>718007</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR (HTA) -- PROMISE</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>09/22/67</gtr:fundingRef><gtr:id>98D9EF65-1F06-45B3-BFEC-EDDEA740AA43</gtr:id><gtr:outcomeId>UDLSk9qBKFc0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>225939</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Advisory and Awards Committee (CTAAC) -- PATCH (grant 1)</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17093/A5343</gtr:fundingRef><gtr:id>E51DE2D4-272D-4FB1-B82D-71BC094C679C</gtr:id><gtr:outcomeId>qxwDTeJJxs20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1288426</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Trials Advisory and Awards Committee (CTAAC) - Late phase study - PATCH</gtr:description><gtr:end>2021-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C17093/A12443</gtr:fundingRef><gtr:id>6993EE9B-D1CD-48D7-B39E-987044053AC5</gtr:id><gtr:outcomeId>5444deaf23db26.58274443</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3598674</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Add-Aspirin trial - CRUK (CTAAC) grant</gtr:description><gtr:end>2023-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C471/A15015</gtr:fundingRef><gtr:id>1D0F580A-344D-49ED-AFA1-287559C64ADE</gtr:id><gtr:outcomeId>WGRpw13FQxQ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clincal Trial Advisory and Awards Committee (CTAAC) -- RADICALS</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>1FED5B0D-B420-4AA6-989A-FA65A869BC15</gtr:id><gtr:outcomeId>j6LBhhEJgMa0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3124812</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Health Technology Assessment Programme (HTA)</gtr:department><gtr:description>NIHR (HTA) funding for Add-Aspirin trial</gtr:description><gtr:end>2023-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/01/38</gtr:fundingRef><gtr:id>922950E8-B32D-4A07-96A5-BEFC889F0C85</gtr:id><gtr:outcomeId>544fcf86459d90.16977900</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>First results from RT01 demonstrated that dose-escalated radiotherapy was better than standard-dose radiotherapy for men with localised and locally advanced prostate cancer.</gtr:description><gtr:grantRef>MC_U122861330</gtr:grantRef><gtr:id>9528D6D7-51BC-4B49-8BFA-9F2B955272BD</gtr:id><gtr:impact>Standard-of-care was changed in the UK.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>cU939Ypfh21</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>RT01 trial results</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Trial results demonstrated that the addition of radiotherapy to long-term hormone therapy prolongs survival for men with locally advanced, non-metastatic prostate cancer.</gtr:description><gtr:grantRef>MC_U122861330</gtr:grantRef><gtr:id>F999B785-1030-4844-83BB-52A00FF84E1A</gtr:id><gtr:impact>Impact on clinical practice in the UK.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>qxM7VYYWtZ9</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>PR07 trial results</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Interview panel for surgical trials units (Matt Sydes)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CCD2426D-9541-4014-AE56-D88FA805C59A</gtr:id><gtr:outcomeId>bTMLZ5Cmm4C</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation; research arm of RT01 became standard of care</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:guidelineTitle>Prostate cancer: diagnosis and treatment (Full Guideline, Feb 2008)</gtr:guidelineTitle><gtr:id>53088C68-A9B4-49BB-8827-39A02CACC31E</gtr:id><gtr:impact>Initial results of RT01 trial defined standard dose of radiotherapy for prostate cancer (74Gy in 2Gy fractions)</gtr:impact><gtr:outcomeId>JGjvySW96Uv</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.nice.org.uk/CG58</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>STAMPEDE protocol</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>B0F839FB-C404-4B96-8389-96C93D531294</gtr:id><gtr:impact>Results of PR07 in Nov-2011 led to a change in the control arm of the STAMPEDE trial for a substantive subset of patients. Led to the development of a further randomised question in STAMPEDE which drew in additional funding.</gtr:impact><gtr:outcomeId>pdkvhv9JnBQ</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RT01 citation in ESMO guidelines</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:guidelineTitle>Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</gtr:guidelineTitle><gtr:id>24D97550-D7CC-4731-ABB0-1FFBEE4FDFA4</gtr:id><gtr:impact>Research arm of RT01 becoming standard of care.</gtr:impact><gtr:outcomeId>WpvHXtrimek</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical guidelines; post-surgery, men should be considered for trials like RADICALS</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:guidelineTitle>Prostate cancer: diagnosis and treatment (Full guidelines, Feb 2008)</gtr:guidelineTitle><gtr:id>0F00C12B-2EB0-40BA-B09E-BEEEE563884D</gtr:id><gtr:impact>Post-surgery, men should be considered for clinical trials like RADICALS eg participation in a clinical trial is the standard of care</gtr:impact><gtr:outcomeId>n9zeYP9dvhT</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Add-Aspirin is a phase III, double-blind, placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. It is currently in the set-up phase and funding has been secured from CRUK. Further funding applications are ongoing.</gtr:description><gtr:id>53DCF87D-3EDB-4B82-8322-0C428270CFE0</gtr:id><gtr:impact>under development. 
Novel methodology proposed including 4 individually powered trials integrated into one over-arching trial</gtr:impact><gtr:outcomeId>hH1QUrY1td1</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Add-Aspirin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Two randomised controlled trials in overlapping groups of patients.
(1) In men who have recently undergone surgery for prostate cancer, should radiotherapy by used:
:: Adjuvantly in all men
:: In some men, only if PSA values start to increase
(2) In men having radiotherapy to the prostate bed any time after surgery for prostate cancer, how much hormone therapy, if any, should also be given:
:: None
:: Short-term - 6 months
:: Long-term - 2 years</gtr:description><gtr:id>793E32CC-61DD-4312-A633-E51E246C5920</gtr:id><gtr:impact>No results due for many years yet.
Trial designed to efficiently address a number of questions simultaneously.</gtr:impact><gtr:outcomeId>kQYdueNZETc</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>RADICALS</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=1762</gtr:url><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Standard of care for men with locally advance prostate cancer was hormone therapy alone, although many UK centres were also already giving radiotherapy. This randomised controlled trial assessed:
(1) Hormone therapy alone
(2) Hormone therapy plus radiotherapy
Recruitment started in Canada in 1995, but most patients were recruited in the UK between 1999 and 2005</gtr:description><gtr:id>CF085C08-18B6-44F7-A89E-E2B3205C9218</gtr:id><gtr:impact>A survival advantage was demonstrated with the addition of radiotherapy.
Standard practice in the UK has changed, including in the backbone of therapy in this group of men in the STAMPEDE trial.
First results were published in 2011. Updated results have been presented but the data are not yet published.</gtr:impact><gtr:outcomeId>eUSZyVs7Zz6</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PR07</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN24991896</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Testing the use of Multi-Parametric Magnetic Resonance Imaging (MP-MRI) in the diagnosis of prostate cancer</gtr:description><gtr:id>12591451-8F97-41B7-99A7-F55BA6D87535</gtr:id><gtr:impact>The results aim to inform the role of MP-MRI in the diagnostic pathway for prostate cancer.</gtr:impact><gtr:outcomeId>bxf6c5nKMQz</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>PROMIS</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN16082556/</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Radiotherapy to the prostate for men whose cancer has already spread elsewhere
Recruitment opened: Jan-2013
Ongoing</gtr:description><gtr:id>C603F72B-0C5B-4321-835E-8C0B15185E9C</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>5458f2cb32ff05.99349885</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>STAMPEDE - M1|RT comparison (AH)</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00268476</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>All patients receive standard care (arm &amp;quot;A&amp;quot;) which is long-term hormone therapy. A subset of patients with disease that hasn't spread should also receive radiotherapy. The trial assesses a number of different treatments in addition to this standard of care:
(B) zoledronic acid - a bisphosphonate
(C) docetaxel - a chemotherapy
(D) celecoxib - a cox-2 inhibitor
(E) zoledronic acid + docetaxel 
(F) zoledronc acid + celecoxib
(G) abiraterone - a CYP-17 inhibitor
(H) radiotherapy to the prostate; only in men whose disease has already spread.

Notable dates:
Oct-2005: accrual initiated to arms A, B, C, D, E and F
Apr-2011: accrual stopped early to arms D and F
Nov-2011: accrual initiated to arm G
Jan-2013: accrual initiated to arm H
Mar-2013: accrual completed to arms B, C and E</gtr:description><gtr:id>137EEB2E-62AE-4E0D-9524-5A2F5C030F27</gtr:id><gtr:impact>Implemented a number clinical trial method: multi-arm multi-stage trial. Demonstrated the practice and then further extended it by incorporating new research comparisons. Now the largest randomised controlled trial of treatment for me with prostate cancer.</gtr:impact><gtr:outcomeId>M1sEMbhzFiX</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>STAMPEDE - original comparisons (ABCDEF)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00268476</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Bisphosphonate drug for men with metastatic prostate cancer.</gtr:description><gtr:id>32E4BA88-86F6-4142-A393-CBFA8C487A17</gtr:id><gtr:impact>Demonstrated an improvement in overall survival by using a bisphosphonate drug for non-metastatic prostate cancer. Did not change practice.
Led to development of STAMPEDE.</gtr:impact><gtr:outcomeId>Dy8ecHWGCRQ</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PR05</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN38477744</gtr:url><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Using traditional machines, radiotherapy dose were limited by toxicity. A new generation of radiotherapy machines could use &amp;quot;conformal&amp;quot; technique which allowed for shaping of the radiotherapy beams around normal structures. This should decrease toxicity. If toxicity is increased with normal doses, could the dose be increased and would this allow improved short and long-term outcomes. Patients were randomised to:
:: Standard - 64 Gray over 32 fractions
:: Escalated - 74 Gray over 37 fractions</gtr:description><gtr:id>9AF584C9-7673-4B98-A209-E04D4B3DF06C</gtr:id><gtr:impact>The trial improved short-term outcomes in 2007 and this led to a change in the standard of care. However, this approach has not demonstrated an improvement in overall survival in current, updated analyses. These results have been presented and a paper will soon be submitted.</gtr:impact><gtr:outcomeId>KLUmLw1xkcN</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>RT01</gtr:title><gtr:type>Therapeutic Intervention - Radiotherapy</gtr:type><gtr:url>http://www.controlled-trials.com/ISRCTN47772397</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Recruitment opened: Nov-2011
Recruitment closed: Jan-2014
Follow-up ongoing</gtr:description><gtr:id>B3A9971F-06CF-4CD4-AC29-EADA84532757</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>5458f24117ecf3.07455981</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>STAMPEDE - abiraterone comparison (AG)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT00268476</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Bisphosphonate drug for non-metastatic prostate cancer</gtr:description><gtr:id>A439AED7-293C-4B9C-BEE9-D09E9DB2C44F</gtr:id><gtr:impact>Demonstrated no improvement in overall survival by using a bisphosphonate drug for non-metastatic prostate cancer.
Led to development of STAMPEDE.</gtr:impact><gtr:outcomeId>fYyAr78TiWM</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PR04</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN61384873</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN61384873</gtr:url><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>PATCH is a randomised, non-inferiority, phase III trial comparing the clinical efficacy and side effect profile of transdermal oestrogen patches with Luteinising Hormone Releasing Hormone agonists (LHRHa) in the treatment of locally advanced and metastatic prostate cancer. 
Transcutaneous oestrogen avoids first-pass hepatic metabolism and therefore is not expected to be associated with the same level of cardiovascular (CVS) system toxicity as oral oestrogen. 

The primary outcome measures will be overall survival and progression-free survival. The secondary outcome measures include prostate cancer specific survival, hormone levels, CVS and other toxicity, and quality of life. 

Data from the trial so far have shown promising evidence of the safety and efficacy of the oestrogen patches. Results from the first stage of the trial which aimed to assess the safety and activity of the patches have been published (n= 254), showing the patches produced castrate levels of testosterone similar to LHRHa, with no evidence of excess CVS toxicity. During the second stage, a pre-planned interim analysis (n=638) reviewed by the Independent Data Monitoring Committee in June 2013 led to the trial being extended for a phase III evaluation of the patch efficacy.

For a summary of a systematic review on the use of parenteral oestrogens in prostate cancer undertaken to inform the design of this study please see Appendix H or access the following link: http://www.york.ac.uk/inst/crd/pdf/parentoestrogen.pdf).</gtr:description><gtr:id>F9F659C9-6452-4CBC-A82D-5CCB15AB17DF</gtr:id><gtr:impact>Results from a bone health sub-study embedded within PATCH have shown transdermal oestrogen protects against the bone mineral density loss seen with LHRHa. However, the clinical efficacy of the patches needs confirming within a phase III trial setting before they can be considered as part of standard care in prostate cancer.</gtr:impact><gtr:outcomeId>s4Uazf3Bh59</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PATCH</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.tevauk.com/mediafile/id/7480.pdf</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Recruitment opened: Jul-2014
Unlikely that this combination of treatments, which have a compelling case for being combined, would have been put together without an academic trials group taking the lead</gtr:description><gtr:id>5A5D7EFC-30A1-4B01-893A-95F6874DA4CD</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>5458f33723ec45.24438588</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>STAMPEDE - enzalutamide and abiraterone comparison (AJ)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial.</gtr:description><gtr:id>09B15788-8F8A-43D8-B41C-D61B91219672</gtr:id><gtr:impact>Due to the size and scope of the planned trial (;10,000 participants with four different tumour types), the database is expected to provide a rich resource of information for use in future research beyond the original trial question. The data will be made available to other researchers via an application process.</gtr:impact><gtr:outcomeId>5459ffa8639734.96402979</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Add-Aspirin trial database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Quality of life data from RT01 trial</gtr:description><gtr:id>F1A442E7-696C-4EC5-932E-4331097992E5</gtr:id><gtr:impact>None yet. Analysis led by ICR CTSU after transfer.</gtr:impact><gtr:outcomeId>SXzCRRmNNqk</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RT01 Quality of Life dataset</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Long-term prospectively-collected patient-level data from the PR07 RCT of hormone therapy alone vs hormone therapy plus radiotherapy.</gtr:description><gtr:id>A1AE6E06-FC6A-402D-AABD-8FE7F7F5A5A4</gtr:id><gtr:impact>(1) First trial results were published in 2011
(2) Long-term trial results were presented in 2012 and will soon be submitted for publication
(3) External collaborators are trying to retrospectively collect biological samples and should be able to access data if they are successful</gtr:impact><gtr:outcomeId>GMFnCiRFpdh</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PR07 dataset</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Many trials now receive requests so that their prospectively collected data can be used by external (or internal) groups for secondary purposes, including linkage to other studies. A processes used by MRC CTU Cancer Group (which is not yet at Unit SOP) has been shared with many groups and has facilitated the sharing of data between many other groups. A template sets out this process.</gtr:description><gtr:id>2AA23132-C287-4CC1-9168-56D1685D40F6</gtr:id><gtr:impact>Many groups have found it simple to assess incoming requests and to share data where appropriate.</gtr:impact><gtr:outcomeId>H8J9Jz5wZXv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Data release request form</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Clinical database for RADICALS</gtr:description><gtr:id>656098EE-D88D-4D1F-9482-879AB125D4F2</gtr:id><gtr:impact>Results awaited</gtr:impact><gtr:outcomeId>2B3BD20F65B</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RADICALS database</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Clinical data from the RT01 trial</gtr:description><gtr:id>49E6FB91-6124-44AC-9598-BAD99B27436E</gtr:id><gtr:impact>(1) Randomised data were published in 2007
(2) Updated results publication in 2014
(3) Data have been shared with the RAPPER group at the University of Manchester</gtr:impact><gtr:outcomeId>ptNpi99gMsW</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RT01 clinical database</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>PATCH clinical trial database and repositry of blood and urine samples from trial participants.</gtr:description><gtr:id>E15E83B8-DC4C-4ACE-8696-B63EF8BDB31B</gtr:id><gtr:impact>The data and sample collection are ongoing. Interim analyses of trial data have resulted in a publication (PMID: 18422771) and presentation of results at a number of national and international conferences in 2011.</gtr:impact><gtr:outcomeId>ap8xgEFBn2v</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PATCH data and samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18422771</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Samples of blood, urine and semen from patients at risk of prostate cancer (all patients enroled in PRMIS study) will be used to identify biomarkers of risk for clinically significant prostate cancer (discriminators of low-risk vs high-risk disease).</gtr:description><gtr:id>01948684-2D64-4CB5-B488-652FA19A4276</gtr:id><gtr:impact>Material now being collected. It will not be used until there are sufficient numbers of PROMIS patients with and without evidence of cancer.</gtr:impact><gtr:outcomeId>Auw7Nojejzm</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PROMIS specimen bank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>1. STAMPEDE clinical database 2. STAMPEDE genetic translational substudy database 3. STAMPEDE bone mineral density substudy database</gtr:description><gtr:id>3174CB02-4AF4-4502-A5E8-A94DD6356176</gtr:id><gtr:impact>None, yet. Discussions are ongoing for people to start to gain access.</gtr:impact><gtr:outcomeId>E7808644832</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>STAMPEDE database</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>A drug supply management system tailored to the trial requirements has been developed in-house to provide a secure system for coordinating all aspects of the drug supply process in the study. The drug packaging and distribution team, as well as research staff and pharmacists at participating sites will have web-based access to the system, and it will allow close oversight of the whole process by the Trials Unit team. Input from all of the relevant parties has been sought in developing the system and it has been designed in such a way that it can subsequently be adapted for use in future trials conducted at the unit.</gtr:description><gtr:id>3C8B0489-3309-46A2-80EF-8A5C04663D19</gtr:id><gtr:impact>This in-house system may replace the need to out-source the management of drug supply processes, and so will have cost-saving implications both within Add-Aspirin and for future trials.</gtr:impact><gtr:outcomeId>545a000bf40ee7.93184997</gtr:outcomeId><gtr:title>Add-Aspirin Drug Supply Management System</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>90961264-9B2D-45D8-B97C-34F35F352CA3</gtr:id><gtr:title>Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/456893a622597e342e3251f43582f879"><gtr:id>456893a622597e342e3251f43582f879</gtr:id><gtr:otherNames>Warde P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>CtYwmE8uGQW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E9BDD2A-EACE-417D-900A-641A8A3685A5</gtr:id><gtr:title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>C64E673E706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DFA0297-8F95-4F87-BBEA-4F6C6514EF28</gtr:id><gtr:title>Postoperative radiotherapy after radical prostatectomy: let's work together to tackle the known unknowns.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8c0f9f2a167a9c3c7bdc612ef4685c"><gtr:id>1b8c0f9f2a167a9c3c7bdc612ef4685c</gtr:id><gtr:otherNames>Parker CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5457bf54112fd4.60555296</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>590976D2-38AE-4D24-8AF4-F90A914C9D4A</gtr:id><gtr:title>Applying for ethical approval for research in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e61d9d70d39d7942eb7179fd7d724d3"><gtr:id>8e61d9d70d39d7942eb7179fd7d724d3</gtr:id><gtr:otherNames>Smajdor A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>rRjuiu5qCEf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB5BF99C-6702-4F36-A6C5-C4E34FAF9D3F</gtr:id><gtr:title>Can we deliver randomized trials of focal therapy in prostate cancer?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>5461fd0b8a0d12.30600501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EAA0D2A-1BD7-4FD7-8E09-A4DD001717AE</gtr:id><gtr:title>Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13787_27_22452894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>672EB11B-687D-46AE-86F3-E75588F94389</gtr:id><gtr:title>Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bf1a45a9842156c5330cadbd2eeb56"><gtr:id>41bf1a45a9842156c5330cadbd2eeb56</gtr:id><gtr:otherNames>Stanley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>E5004A076F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAC5DA26-5698-4183-955D-1F6BD2B28FDD</gtr:id><gtr:title>Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et&amp;nbsp;al.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>5940f6b77ddb87.06876442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>883E39F7-5924-4D22-AB88-9ABD8858FF94</gtr:id><gtr:title>Aspirin as a treatment for cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f5fb90f064bddeb754617a9e415b43"><gtr:id>d1f5fb90f064bddeb754617a9e415b43</gtr:id><gtr:otherNames>Phillips I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>doi_13787_013_03_001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A84043B0-E763-4E6C-B02E-58D44BFF71B9</gtr:id><gtr:title>Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f916785d45262e78b21f0f9e558423bf"><gtr:id>f916785d45262e78b21f0f9e558423bf</gtr:id><gtr:otherNames>Vergis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>B0918570F1A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64FDE10E-B298-42E8-8883-7C588414BF94</gtr:id><gtr:title>Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5dd390fff4eb82dd140c867c64a164"><gtr:id>db5dd390fff4eb82dd140c867c64a164</gtr:id><gtr:otherNames>Gulliford SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>25CE03757E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E9AC14D-6BC9-45A5-8415-B4E1F336BD3C</gtr:id><gtr:title>The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>UX2noxrKBc4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6CB20FC-ABBC-4242-BE08-E3F4CDCA71E5</gtr:id><gtr:title>Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f916785d45262e78b21f0f9e558423bf"><gtr:id>f916785d45262e78b21f0f9e558423bf</gtr:id><gtr:otherNames>Vergis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>iwsWfJKrHQY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2FCC233-225B-486A-84B9-1A11073DB1A4</gtr:id><gtr:title>Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36a0787b7828d604408c3fe3a21119b8"><gtr:id>36a0787b7828d604408c3fe3a21119b8</gtr:id><gtr:otherNames>Gillessen S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>59536a12abf076.46918661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7560F2-6885-4A54-982E-FB1874D51B35</gtr:id><gtr:title>Clinical evidence for the use of aspirin in the treatment of cancer.</gtr:title><gtr:parentPublicationTitle>Ecancermedicalscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1754-6605</gtr:issn><gtr:outcomeId>pm_13787_27_23589726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C2AF3F1-CF6A-48C1-BDCF-B9C0389CF42E</gtr:id><gtr:title>A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc4389ae07293d859ae1a38ce4928c24"><gtr:id>fc4389ae07293d859ae1a38ce4928c24</gtr:id><gtr:otherNames>Fachal L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5457bf545e2736.26970986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D703E25A-68EC-4B50-97B3-8627EC11002E</gtr:id><gtr:title>STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>B7E212CFFAE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A606E7D-2B01-4C11-A44D-519E17397CDD</gtr:id><gtr:title>Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5dd390fff4eb82dd140c867c64a164"><gtr:id>db5dd390fff4eb82dd140c867c64a164</gtr:id><gtr:otherNames>Gulliford SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pTYGe5Fbs6M</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D32E0CC-E27C-40C0-81C2-D63BF885BB9D</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58b98f57a1f775.39638054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95EEBD22-1080-4296-AAD8-B80187B1223A</gtr:id><gtr:title>More multiarm randomised trials of superiority are needed.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5457b91932ce02.21669672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>088925B3-8C2F-40F6-992D-BE5F2FDF8A9F</gtr:id><gtr:title>Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012;61:443-51.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_13787_27_23018161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5693077-B47A-4A1B-BDD1-F6BB93BB9B9E</gtr:id><gtr:title>Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>893B46B2665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71DC66CB-8141-47A6-80F5-46F8DB584D64</gtr:id><gtr:title>Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397).</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d0b20cc7b4a60cc062341333892bd7"><gtr:id>68d0b20cc7b4a60cc062341333892bd7</gtr:id><gtr:otherNames>Buettner F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>751D9850245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>621279F9-7EAD-4C9C-AD08-013859D71563</gtr:id><gtr:title>When Should Radiotherapy Be Used after Radical Prostatectomy? The RADICALS-RT Trial</gtr:title><gtr:parentPublicationTitle>British Journal of Medical and Surgical Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>BWZSDcYY6g1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AAC3EAA-3E83-445F-AD9D-E7D9077A4DD1</gtr:id><gtr:title>A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5dd390fff4eb82dd140c867c64a164"><gtr:id>db5dd390fff4eb82dd140c867c64a164</gtr:id><gtr:otherNames>Gulliford SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>YWBS87sgNWX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>990FBADF-C2DA-4250-8195-FE907EDB55E1</gtr:id><gtr:title>Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc375f14ceef8e17abe7868570792812"><gtr:id>dc375f14ceef8e17abe7868570792812</gtr:id><gtr:otherNames>Sylvester RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>56d573803e9dc6.18022251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63409CE6-09B1-4332-90D0-44C9DB63AE3E</gtr:id><gtr:title>Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7744e8e09b3d0fd0cf776341fadf5194"><gtr:id>7744e8e09b3d0fd0cf776341fadf5194</gtr:id><gtr:otherNames>South A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>56d5737fc97886.40936996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47C3A653-22B8-401A-BE2C-8FD0A908BE7B</gtr:id><gtr:title>Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13787_27_22978443</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF272A54-8F64-4AF9-BAD9-09C13645DCC9</gtr:id><gtr:title>RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>3C7DBC43EAC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8F7294D-83AA-4E5A-83FC-609C822AFF39</gtr:id><gtr:title>Adjuvant radiotherapy after surgery for prostate cancer.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>C92C5FB7C97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F2CF35A-7709-472B-8BA4-8F55658E5A2C</gtr:id><gtr:title>The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.</gtr:title><gtr:parentPublicationTitle>Ecancermedicalscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76f55bf11bf9112330ef9840251dd7d0"><gtr:id>76f55bf11bf9112330ef9840251dd7d0</gtr:id><gtr:otherNames>Smith T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1754-6605</gtr:issn><gtr:outcomeId>544fc0b7e23d18.35657910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ECDE6A1-5527-4104-B733-22C6BA853277</gtr:id><gtr:title>Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ae4b9f57e5711d5384674dd031f3c1e"><gtr:id>8ae4b9f57e5711d5384674dd031f3c1e</gtr:id><gtr:otherNames>Mangar SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>2EB139C913F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36BE5BF4-D547-4F65-A6F4-1EA9478E0E24</gtr:id><gtr:title>Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>DEA68446CD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB303FE0-42B6-4EFC-8F24-1D7410AA80CF</gtr:id><gtr:title>Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>4A717E31B18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F3CAAD0-998B-48C2-89AE-2F00F6AE7D05</gtr:id><gtr:title>Parenteral oestrogen in the treatment of prostate cancer: a systematic review.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46fbd16cf76821f262f59f64f1501980"><gtr:id>46fbd16cf76821f262f59f64f1501980</gtr:id><gtr:otherNames>Norman G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>CBBB114126F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C11BF72B-7A56-4E66-B79D-EF2028E8C209</gtr:id><gtr:title>Survival with Newly Diagnosed Metastatic Prostate Cancer in the &amp;quot;Docetaxel Era&amp;quot;: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5457bf54394366.75428053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84D632D0-A769-4691-BD06-151BC77FE6FD</gtr:id><gtr:title>A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5457bf54b05f38.90787561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C765821-0794-4FD0-8D2E-94BB0DDFE46C</gtr:id><gtr:title>Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8c0f9f2a167a9c3c7bdc612ef4685c"><gtr:id>1b8c0f9f2a167a9c3c7bdc612ef4685c</gtr:id><gtr:otherNames>Parker CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>pm_13787_27_23578233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB6C87E8-7C24-49C6-9FBE-430E22B765CA</gtr:id><gtr:title>Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_13787_27_21847126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93218F2C-6B1B-432D-9801-D9B9C0223642</gtr:id><gtr:title>Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a28fc121b1e2b4b05013e918f994750d"><gtr:id>a28fc121b1e2b4b05013e918f994750d</gtr:id><gtr:otherNames>Syndikus I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>6D502E19CE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00E603F6-25D3-4793-9B50-C9DF8AF3A0C6</gtr:id><gtr:title>PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>56c49d7045bc44.96372614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72D028BE-0166-42DA-BA55-0CD058256391</gtr:id><gtr:title>The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>56c49d7075db06.13033623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97612F5F-C1B8-4A5A-85DA-4BFB5F204D86</gtr:id><gtr:title>Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5457bf5483e831.04764696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A74D24F5-09E9-4D5E-8BB2-4E81DBB1A6F7</gtr:id><gtr:title>Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c046ae6f178734e3c27748ade971b75c"><gtr:id>c046ae6f178734e3c27748ade971b75c</gtr:id><gtr:otherNames>Brundage M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737e822f38.21533292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A74FB750-CF6C-4284-8594-A6787811AFCC</gtr:id><gtr:title>Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>C53CCEB7B9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA1B3B3-D682-40D5-8A30-51F0D7C4BB12</gtr:id><gtr:title>Parenteral oestrogen: effective and safer than both oral oestrogen and contemporary androgen deprivation therapy for prostate cancer?</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1723c3d97e582f950b8eb47bb0298c31"><gtr:id>1723c3d97e582f950b8eb47bb0298c31</gtr:id><gtr:otherNames>Shah SI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-1805</gtr:issn><gtr:outcomeId>5444d51a438862.21700189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF6352F8-4B57-446A-A8FF-4C8B219B78A5</gtr:id><gtr:title>Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8c0f9f2a167a9c3c7bdc612ef4685c"><gtr:id>1b8c0f9f2a167a9c3c7bdc612ef4685c</gtr:id><gtr:otherNames>Parker CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_13787_27_23489869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40BFA60A-38AE-4B98-9DEA-F0FC1FBCD1BF</gtr:id><gtr:title>The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>E3502DF0FB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A9AE0D0-9A06-423A-BCA8-DBCAC3335A68</gtr:id><gtr:title>Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: a randomized controlled trial for men with prostate cancer.</gtr:title><gtr:parentPublicationTitle>International journal of urology : official journal of the Japanese Urological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0919-8172</gtr:issn><gtr:outcomeId>dv5sWpY5oWC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09A9434F-1CB6-4739-9044-39E1B507A827</gtr:id><gtr:title>The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/675570658e2e1d0dbdcfb855b2d08e81"><gtr:id>675570658e2e1d0dbdcfb855b2d08e81</gtr:id><gtr:otherNames>Stephens RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>D993D7E5FB1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBD07065-C2A1-4533-8C9A-0A607DE4CB6A</gtr:id><gtr:title>Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af0707d338e2c1c3c05688ae01f64aed"><gtr:id>af0707d338e2c1c3c05688ae01f64aed</gtr:id><gtr:otherNames>Ahmed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58b69d8d9b0137.33010439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D5A88FD-2B8C-46FE-A586-C7CD6521542A</gtr:id><gtr:title>Potential pitfalls in the design and reporting of clinical trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>b3EofPZmnBo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D90FA692-CF92-446B-9DED-8F804C14E952</gtr:id><gtr:title>Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>56d5737f99c8f6.82782342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54F35366-5F4C-4B8B-B75F-559D5976B697</gtr:id><gtr:title>Re: Sanoj Punnen, Matthew R. Cooperberg, Anthony V. D'Amico, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.05.025: Re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer:</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>pm_13787_27_23953599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F949F056-2148-4DCA-A490-4EDA683FE23A</gtr:id><gtr:title>Prostate cancer staging tables-A predictive model for the UK</gtr:title><gtr:parentPublicationTitle>British Journal of Medical and Surgical Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75cbf8624753d6dd11be05a8574b1d7b"><gtr:id>75cbf8624753d6dd11be05a8574b1d7b</gtr:id><gtr:otherNames>Bott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>E94AC557E96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86EB271B-0F37-41B7-941A-B5E340F9ED80</gtr:id><gtr:title>Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc1cebf8d7bdc29258b3035f4f93eba7"><gtr:id>cc1cebf8d7bdc29258b3035f4f93eba7</gtr:id><gtr:otherNames>Andreassen CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58b69d8dd6d0a5.41306724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45103F9A-528F-4F23-AC9E-0091D3904919</gtr:id><gtr:title>Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>A649218FB7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50B5040B-CBE3-4845-A0FD-01F4A6F4CDE9</gtr:id><gtr:title>Speeding up the evaluation of new agents in cancer.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/541a4254e1d3febac0196c37bb2533c3"><gtr:id>541a4254e1d3febac0196c37bb2533c3</gtr:id><gtr:otherNames>Parmar MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>BaMHUqsgGMe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>124EB5E8-E57C-401F-8BD7-F8B9212A9ACC</gtr:id><gtr:title>Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13787_27_23465742</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>109A5EE2-D72B-4B2C-A3E0-0929C1D601C5</gtr:id><gtr:title>Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Oncology &amp; hematology review</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f5fb90f064bddeb754617a9e415b43"><gtr:id>d1f5fb90f064bddeb754617a9e415b43</gtr:id><gtr:otherNames>Phillips I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-3815</gtr:issn><gtr:outcomeId>5444d4c314c295.73279527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DF2F5F2-47DF-48CA-B513-CA96345F625C</gtr:id><gtr:title>Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a2b4a60143f694fb37017f02d8dd28a"><gtr:id>9a2b4a60143f694fb37017f02d8dd28a</gtr:id><gtr:otherNames>Kerns SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>596bcfcb3b2241.29523464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73E71184-AFDF-46B5-8D34-C336A123713C</gtr:id><gtr:title>Resolving the optimal timing of radiotherapy after radical prostatectomy: the need for further research.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>E53ECB6B275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F4371DB-D7F7-46D1-B2F9-4828B534FDD3</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d98c29beb6dc28d0f861418f49d65494"><gtr:id>d98c29beb6dc28d0f861418f49d65494</gtr:id><gtr:otherNames>Ahmed H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b98c09ba4404.16448606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>401610F4-8617-45A7-BEFE-3AF2E589DE8F</gtr:id><gtr:title>Re: Ute Ganswindt, Arnulf Stenzl, Michael Bamberg and Claus Belka. Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol 2008;54:528-42.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>8EC65B43477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75662DE5-91C1-4662-A042-E84DC29F0ACC</gtr:id><gtr:title>Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbb3d1bce4efe3862425b8b3f06e17ad"><gtr:id>dbb3d1bce4efe3862425b8b3f06e17ad</gtr:id><gtr:otherNames>Kass-Iliyya A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>5a510386b0c860.84073848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7FDB1D1-50D4-4D56-A9E6-8D69B4F576F7</gtr:id><gtr:title>Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>958ED09D70A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5396F2C-7433-47FC-9F5D-BDFD03A70AEF</gtr:id><gtr:title>Modeling late rectal toxicities based on a parameterized representation of the 3D dose distribution.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d0b20cc7b4a60cc062341333892bd7"><gtr:id>68d0b20cc7b4a60cc062341333892bd7</gtr:id><gtr:otherNames>Buettner F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>LFRNnpioyvq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24A8795E-1F4F-42AD-A2D0-F2E3B07A7A03</gtr:id><gtr:title>Prostate radiotherapy after radical prostatectomy: sooner or later?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/142c3099ad7ed7c7b05389bf43f3732c"><gtr:id>142c3099ad7ed7c7b05389bf43f3732c</gtr:id><gtr:otherNames>Catton C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>oLrpz7oW6q8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D107D0B4-66DA-434A-9D65-D902DF67FA44</gtr:id><gtr:title>The dose-response of the anal sphincter region--an analysis of data from the MRC RT01 trial.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d0b20cc7b4a60cc062341333892bd7"><gtr:id>68d0b20cc7b4a60cc062341333892bd7</gtr:id><gtr:otherNames>Buettner F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_13787_27_22520267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB9920A9-6BE3-4562-994B-09520B9C89EF</gtr:id><gtr:title>Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/506a277a3fd26a248bbc73e48feb8711"><gtr:id>506a277a3fd26a248bbc73e48feb8711</gtr:id><gtr:otherNames>Barnett GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>pm_13787_27_22169268</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122861330</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>6FFAED28-939F-4795-9FD1-98511549B3B8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>